The greatest challenges facing the pharmaceutical industry today include changing patient expectations, increased self-medication, difficulties in identifying novel medicines for incurable diseases, high payer scrutiny of pharma-economic performance, the trend for governments to favour prevention over treatment, and access to emerging markets. Partnering with MI helps turn these challenges into opportunities.
"…it was helping me get through my post cancer treatments and my cancer that has been a very very rough journey."
Breast cancer survivor (double mastectomy)
"... this [digital therapeutic] forced me to block out the world and say okay, this moment is mine right now, and I'm going to enjoy this moment for myself."
Testicular cancer survivor (chemotherapy)
"…I felt like it was an actual meditation – like they were actually there with me."
Kidney cancer survivor (immunotherapy)
✓ Delivery of clinical resilience training at scale
✓ Objective data insights and resilience content preferences
✓ Full backend integration for policyholder verification
Rx + DTx Pairing
Improve efficacy & patient experience
Accelerate market access & reimbursement
Generate compound-agnostic revenue
Access actionable patient data
Capture objective biometrics remotely
Augment mental wellbeing assessment
Mobio Interactive’s digital therapeutic platform “AmDTx” is CE MDD Class I and DCB0129 certified; GDPR-, HIPAA- and PHIPA-compliant; and undergoing certification for CE MDR Class IIa, ISO 13485, ISO 9000 and ISO 27001.
Validating the accuracy of our digital biomarkers and the efficacy of our digital theragnostic platform, AmDTx.
Effective and accessible healthcare for every human.